46,770 results match your criteria Hodgkin Disease


A 2020 Vision Into Hodgkin Lymphoma Biology.

Adv Anat Pathol 2020 May 29. Epub 2020 May 29.

Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA.

Hodgkin lymphomas (HLs) are lymphoid neoplasms uniquely characterized by a paucity of neoplastic cells embedded in a supportive heterogenous cellular microenvironment. Although first described in the 19th century, systematic biological understanding of HLs has been hindered due to the challenges presented in studying the complex tumor microenvironment and scarce tumorigenic cells. Recent advances in single-cell isolation and characterization, sensitive mutational analytic tools, and multiplex immunohistochemical strategies have allowed further advances in understanding the development and progression of HL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAP.0000000000000270DOI Listing

A case report of Hodgkin lymphoma in a patient treated with ustekinumab for psoriasis.

Medicine (Baltimore) 2020 May;99(21):e20048

Hematology Unit, First Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Rationale: Ustekinumab is a biological agent that inhibits interleukin 12 and 23 and has been approved for the treatment of moderate and severe plaque psoriasis. There have been case reports that raise concerns about its oncogenic potential. We are the first authors to report a case of Hodgkin lymphoma in a psoriatic patient receiving ustekinumab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020048DOI Listing

Hepatitis B virus infection and the risk of cancer among the Chinese population.

Int J Cancer 2020 Jun 1. Epub 2020 Jun 1.

Department of Infectious Disease, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China.

The relationship between hepatitis B virus (HBV) and non-hepatocellular cancers remains inconclusive. This large case-control study aimed to assess the associations between HBV infection status and multiple cancers. Cases (N = 50 392) and controls (N = 11 361) were consecutively recruited from 2008 to 2016 at the First Affiliated Hospital of Nanjing Medical University. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.33130DOI Listing

Update on Biology of Cutaneous T-Cell Lymphoma.

Front Oncol 2020 12;10:765. Epub 2020 May 12.

Department of Dermatology, Johns Hopkins University, Baltimore, MD, United States.

Cutaneous T cell lymphomas (CTCL) comprise of a heterogeneous group of non-Hodgkin lymphomas derived from skin-homing T cells. Variation in clinical presentation and lack of definitive molecular markers make diagnosis especially challenging. The biology of CTCL remains elusive and clear links between genetic aberrations and epigenetic modifications that would result in clonal T cell expansion have not yet been identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00765DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235328PMC

Non-Hodgkin Lymphoma of the jejunum presenting as perforation peritonitis: A case report.

Ann Med Surg (Lond) 2020 Jul 18;55:131-134. Epub 2020 May 18.

Department of Surgery, Faculty of Medicine, Hasanuddin University Makassar, Indonesia.

Primary gastrointestinal lymphoma is very rare compared to gastrointestinal tract lymphoma arising from secondary to primary nodal disease. Extra nodal lymphoma can involve any part of the gastrointestinal tract, most commonly being the stomach followed by small intestine and ileocecal region. They are indistinguishable from other benign and malignant conditions and are clinically non-specific. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amsu.2020.04.041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251296PMC

Benzene exposure-response and risk of lymphoid neoplasms in Chinese workers: A multicenter case-cohort study.

Am J Ind Med 2020 May 31. Epub 2020 May 31.

Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, Maryland.

Background: While international agreement supports a causal relationship of benzene exposure with acute myeloid leukemia, there is debate about benzene and lymphoid neoplasm risks.

Methods: In a case-cohort study with follow-up of 110 631 Chinese workers during 1972-1999, we evaluated benzene exposure-response for non-Hodgkin lymphoma (NHL), lymphoid leukemias (LL), acute lymphocytic leukemia (ALL), and total lymphoid neoplasms (LN). We estimated benzene exposures using state-of-the-art hierarchical modeling of occupational factors calibrated with historical routine measurements and evaluated cumulative exposure-response using Cox regression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajim.23142DOI Listing

Diffuse large B-Cell lymphoma associated with paraneoplastic Guillain-Barré syndrome: A diagnostic and therapeutic challenge.

Hematol Oncol Stem Cell Ther 2020 May 20. Epub 2020 May 20.

Roswell Park Comprehensive Cancer Centre, Buffalo, NY, USA. Electronic address:

Paraneoplastic neurological syndromes are a rare manifestation of non-Hodgkin lymphoma and can make treatment of these patients more challenging. We report the case of a 67-year-old man with high grade diffuse large B-cell lymphoma who presented with severe paraneoplastic Guillain-Barré syndrome. He was treated with intravenous immunoglobulin therapy and definitive chemoimmunotherapy, and achieved a full neurological recovery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hemonc.2020.05.008DOI Listing

[Checkpoint inhibitors in Hodgkin lymphoma].

Internist (Berl) 2020 May 27. Epub 2020 May 27.

Medizinische Klinik I, Uniklinik Köln, Kerpener Str. 62, 50937, Köln, Deutschland.

Background: Checkpoint blockade contributes to the immunosuppressive microenvironment in classical Hodgkin lymphoma (cHL) and in particular the interaction of Hodgkin cells and macrophages with T‑cells and natural killer cells via programmed cell death 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1).

Objectives: The aim of this article is the evaluation the role and potential of checkpoint blockade in cHL as compared with the results of standard chemo- and radiotherapy.

Methods: We analyzed preclinical and clinical data from phase I and phase II studies with checkpoint blockade in cHL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00108-020-00811-2DOI Listing

Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989-2017.

Leukemia 2020 May 28. Epub 2020 May 28.

Department of Hematology, Amsterdam UMC, University of Amsterdam, LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Cancer Center Amsterdam, Amsterdam, The Netherlands.

Population-based studies of classical Hodgkin lymphoma (cHL) in contemporary clinical practice are scarce. The aim of this nationwide population-based study is to assess trends in primary therapy and relative survival (RS) during 1989-2017. We included 9,985 patients with cHL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-020-0875-0DOI Listing

Biological Difference Between Epstein-Barr Virus Positive and Negative Post-transplant Lymphoproliferative Disorders and Their Clinical Impact.

Front Oncol 2020 8;10:506. Epub 2020 May 8.

Hematology Division, IRCCS Ca' Granda-Maggiore Policlinico Hospital Foundation, Milan, Italy.

Epstein-Barr virus (EBV) infection is correlated with several lymphoproliferative disorders, including Hodgkin disease, Burkitt lymphoma, diffuse large B-cell lymphoma (DLBCL), and post-transplant lymphoproliferative disorder (PTLD). The oncogenic EBV is present in 80% of PTLD. EBV infection influences immune response and has a causative role in the oncogenic transformation of lymphocytes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00506DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225286PMC

Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816.

Leuk Lymphoma 2020 May 26:1-6. Epub 2020 May 26.

Department of Medicine, Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA.

The role of radiotherapy (RT) in the management of advanced Hodgkin Lymphoma (HL) is inadequately defined in this era of functional imaging with PET scan. SWOG-S0816 treated advanced stage Hodgkin lymphoma patients with ABVD+/- escBEACOPP and no RT. We queried whether RT might have benefited patients in S0816 who would have met the GHSG-HD15 criteria for RT by simulating RT use as per HD15 criteria of PET + residual disease ≥2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1768388DOI Listing

Clinical and radiological characteristics of patients with pulmonary marginal zone lymphoma: A single center analysis.

Cancer Med 2020 May 26. Epub 2020 May 26.

Division of Hematology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.

Pulmonary marginal zone lymphoma (PMZL) is the most common non-Hodgkin lymphoma affecting the lung. PMZL is usually an indolent disease. Clinical and radiological variables associated with shorter survival are largely unknown and no consensus exists on preferred treatment strategy in PMZL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3096DOI Listing

Burden of Hodgkin and non-Hodgkin lymphoma in Spain over a 10-year period: productivity losses due to premature mortality.

Expert Rev Pharmacoecon Outcomes Res 2020 May 25:1-5. Epub 2020 May 25.

Department of Health Economics, BCN Health Economics & Outcomes Research S.L. Barcelona , Barcelona, Spain.

Background: Cancer is annually responsible for millions of deaths in Europe and billions of euros in productivity losses; the estimated mortality rate of lymphoma was of 7.07 per 100,000 individuals in Spain in 2018. This study aimed to evaluate the burden that lymphoma mortality represents for the Spanish society. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737167.2020.1769478DOI Listing

Percussion assisted radiation therapy in Hodgkin lymphoma allows a marked reduction in heart dose.

Radiother Oncol 2020 May 21. Epub 2020 May 21.

Department of Oncology, Division of Radiation Oncology, Lausanne University Hospital and University of Lausanne, Switzerland.

Background And Purpose: Early-stage Hodgkin lymphoma (HL) is a highly curable disease but the treatment can induce late complications many years later. Irradiation of the healthy heart is inevitable during radiation treatment of mediastinal sites. We developed a novel method to induce a prolonged apnea-like state that can help decrease the dose to organs at risk during radiation therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2019.11.009DOI Listing

The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma.

Br J Haematol 2020 May 23. Epub 2020 May 23.

Plymouth University Hospitals NHS Trust, Plymouth, UK.

This is a 5-year real-world study of 65 patients treated with ibrutinib for relapsed/refractory mantle cell lymphoma across the UK and Ireland. Ibrutinib was well tolerated with no fatal adverse events. The median progression-free survival and overall survival (OS) was 12 and 18·5 months, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16739DOI Listing

Serum Uric Acid Levels and Non-Motor Symptoms in Parkinson's Disease.

J Parkinsons Dis 2020 May 22. Epub 2020 May 22.

King's College London, Department of Neurosciences, Institute of Psychiatry, Psychology & Neuroscience, De Crespigny Park, London, United Kingdom.

Background: Previous studies have identified low serum uric acid (SUA) levels as a risk factor for the development of Parkinson's disease (PD). Prodromal PD mainly manifests as a complex of non-motor features, but the association between SUA levels and nonmotor symptoms (NMS) burden level in advanced PD patients is poorly studied.

Objective: To determine the association between SUA levels and NMS in PD patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JPD-201988DOI Listing

Hodkgin lymphoma concomitant of tuberculosis, a therapeutic challenge for multidisciplinary management.

Cancer Radiother 2020 May 19. Epub 2020 May 19.

Department of Radiation Oncology, Institut Curie, 25, rue d'Ulm, 75005 Paris, France; University of Versailles, St Quentin, France.

Hodgkin lymphoma (HL) is a disease characterized by a high curability rate, and the treatment benefit-risk balance must be carefully addressed to achieve complete disease control with low risk of long-term toxicities. Most patients are treated with a combination of chemotherapy and radiotherapy, after disease staging and response to treatment evaluated by FDG PET/CT. We report the case of a 28-year-old patient concomitantly diagnosed of a Hodgkin lymphoma and active tuberculosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canrad.2020.02.005DOI Listing

Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis.

Cancers (Basel) 2020 May 20;12(5). Epub 2020 May 20.

Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.

Lymphoma is listed among the neoplasias with a high risk of venous thromboembolism (VTE). Risk factors for VTE appear to differ from risk factors in solid tumors. We review the literature of the last 20 years for reports identifying these risk factors in cohorts consisting exclusively of lymphoma patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12051291DOI Listing

Vanishing Bile Duct Syndrome Preceding the Diagnosis of Hodgkin Lymphoma.

ACG Case Rep J 2020 Feb 2;7(2):e00336. Epub 2020 Mar 2.

Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, MN.

Vanishing bile duct syndrome is an acquired liver disease characterized by the progressive destruction and loss of intrahepatic bile ducts. It usually signifies end-stage cholestatic liver disease and is characterized by ductopenia on liver biopsy specimen. We present a case of vanishing bile duct syndrome as the presenting symptom in a patient with Hodgkin lymphoma with subsequent improvement after adequate treatment of the lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14309/crj.0000000000000336DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209801PMC
February 2020

Current Use and Trends in Hematopoietic Cell Transplantation in the United States.

Biol Blood Marrow Transplant 2020 May 10. Epub 2020 May 10.

Center for International Blood and Marrow Transplant Research, Milwaukee, WI; Department of Medicine, Medical College of Wisconsin, Milwaukee.

Hematopoietic cell transplantation (HCT) is a well-established treatment to control and/or cure many malignant and non-malignant diseases involving the hematopoietic system and some solid tumors. We report information about HCT procedures performed in the United States (US) in 2018 and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research® (CIBMTR®). Overall, compared to 2017, the numbers of allogeneic transplant in the US increased by 1% and numbers of autologous transplants decreased by 5%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.04.013DOI Listing

Lymphopenia at diagnosis predicts survival of patients with immunodeficiency-associated lymphoproliferative disorders.

Ann Hematol 2020 May 20. Epub 2020 May 20.

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.

The number of patients who are administered immunosuppressive agents has been increasing. Accordingly, more patients face higher risks for developing immunodeficiency-associated lymphoproliferative disorders (LPD). Although immunodeficiency-associated LPD are distinct from other lymphoid neoplasms in terms of their immunocompromised backgrounds, little is known about the impact of lymphopenia at diagnosis on survival in patients with these LPD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04084-5DOI Listing

New ST623 of Cryptococcus neoformans isolated from a patient with non-Hodgkin's lymphoma in the Brazilian Amazon.

Ann Clin Microbiol Antimicrob 2020 May 20;19(1):20. Epub 2020 May 20.

Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas-HEMOAM, Manaus, AM, Brazil.

Background: Cryptococcosis is a disease of wide geographic distribution. It is most critical when it affects immunocompromised patients, with AIDS, tuberculosis or other diseases that require prolonged hospitalization.

Methods: This study described a case report, molecular epidemiology, the phylogenetic relationship, along with antifungal susceptibility test of a new ST 623 of C. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12941-020-00361-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238607PMC

Classic Hodgkin Lymphoma: A Nonclassic Presentation.

J Pediatr Hematol Oncol 2020 May 19. Epub 2020 May 19.

Division of Pediatric Hematology/Oncology, University of California Davis Medical Center, Sacramento, CA.

Hodgkin lymphoma classically presents as lymphadenopathy with contiguous spread with or without associated B symptoms including night sweats, weight loss, and fever. With timely diagnosis and treatment, this is a potentially curable disease. This report describes a unique case of Hodgkin lymphoma that presented with localized back pain without overt evidence of lymph node involvement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000001825DOI Listing

Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy.

Br J Haematol 2020 May 19. Epub 2020 May 19.

Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA.

Patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) have limited options for salvage, and checkpoint blockade therapy (CBT) has little efficacy. Usage in solid malignancies suggests that CBT sensitises tumours to subsequent chemotherapy. We performed the first analysis of CBT on subsequent NHL treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16756DOI Listing

Relationship between rabbit anti-thymocyte globulin and development of PTLD and its aggressive form in renal transplant population.

Ren Fail 2020 Nov;42(1):489-494

Institute of Medical Sciences, Faculty of Medicine, University of Liverpool, Liverpool, UK.

: The aim of our study is to explore the relationship of rabbit anti-thymocyte globulin (R-ATG) on development of post-transplant lymphoproliferative disease (PTLD) and its aggressive forms (monomorphic PTLD and Hodgkin lymphoma) in renal transplant recipients.: All patients diagnosed with PTLD post-renal transplant in the United States' Organ Procurement and Transplantation Network from 2003 till 2013 and followed up till 2017 were retrospectively reviewed. Multi-variable logistic regression analysis assessed association of R-ATG to development of PTLD and its aggressive form. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0886022X.2020.1759636DOI Listing
November 2020
0.775 Impact Factor

The Role of Microbial Translocation and Immune Activation in AIDS-Associated Non-Hodgkin Lymphoma Pathogenesis: What Have We Learned?

Crit Rev Immunol 2020 ;40(1):41-51

Cedars-Sinai Cancer and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90095.

Human immunodeficiency virus (HIV) infection is associated with greatly increased risk for development of non-Hodgkin lymphoma (NHL). Nearly all acquired immunodeficiency syndrome (AIDS)-associated NHL (AIDS-NHL) is of B-cell origin. Two major mechanisms are believed to contribute to the genesis of AIDS-NHL: (1) loss of immunoregulation of Epstein-Barr virus (EBV)+ B cells, resulting from impaired T-cell function late in the course of HIV disease and (2) chronic B-cell activation, leading to DNA-modifying events that contribute to oncogene mutations/ translocations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1615/CritRevImmunol.2020033319DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241309PMC
January 2020

ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.

Am Soc Clin Oncol Educ Book 2020 May;40:302-313

University of Chicago, Chicago, IL.

Novel immunotherapies and small molecular inhibitors are transforming our approach to previously treated and newly diagnosed patients across the spectrum of non-Hodgkin lymphomas (NHLs). Anti-CD19 CAR T cells are now indicated for the treatment of relapsed/refractory aggressive B-cell lymphomas after at least two previous lines of therapy in which durable remissions are achieved in approximately 40% of previously incurable patients. Second-line chemoimmunotherapy remains the standard of care at first relapse, but poor outcomes with conventional treatment in this setting creates an appealing rationale for earlier use of CAR T cells, which is currently under investigation, along with even earlier use in selected high-risk patients in the frontline setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_279043DOI Listing

Potential of Circulating Tumor DNA for the Management of Patients With Lymphoma.

JCO Oncol Pract 2020 May 18:JOP1900691. Epub 2020 May 18.

Université Claude Bernard Lyon-1, Université de Lyon, Lyon, France.

The characterization of circulating tumor-derived DNA (ctDNA) has recently emerged in the field of oncology as a powerful method to identify tumor-specific genetic aberrations using peripheral blood testing. Several technical precautions are needed at the pre-analytic stage (given the short half-life of free nucleic acids in plasma), and numerous techniques-with different sensitivities-are available to identify these molecular aberrations, ranging from the detection of single point mutations to extended genetic screening panels. Although a "liquid biopsy" cannot be substituted for the pathological examination of tissue specimens for diagnostic purposes, it can sometimes complement pathology results or serve as a proxy approach for particular lymphoma presentations where biopsies are sometimes difficult to perform. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.19.00691DOI Listing

Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.

Cancer Med 2020 May 18. Epub 2020 May 18.

Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.

RSK2 is a serine/threonine kinase downstream signaling mediator in the RAS/ERK signaling pathway and may be a therapeutic target in mantle cell lymphoma (MCL), an almost incurable disease subtype of non-Hodgkin lymphoma. In this study, serine-227 (RSK2 ) in the N-terminal kinase domain (NTKD) of RSK2 was found to be ubiquitously active in five MCL-derived cell lines and in tumor tissues derived from five MCL patients. BI-D1870, an inhibitor specific to RSK2-NTKD, caused RSK2 dephosphorylation, and thereby, induced dose-dependent growth inhibition via G /M cell cycle blockade and apoptosis in four of the five cell lines, while one cell line showed only modest sensitivity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3136DOI Listing

Recent advances in understanding and managing cutaneous T-cell lymphomas.

F1000Res 2020 5;9. Epub 2020 May 5.

Department of Dermatology, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria.

Cutaneous T-cell lymphomas (CTCLs) comprise a heterogeneous group of extranodal non-Hodgkin lymphomas involving primarily the skin and mycosis fungoides is its most frequent entity. Whereas most patients show an indolent course in early disease (clinical stages IA to IIA), some patients progress to advanced disease (stage IIB or higher), and the 5-year survival rate is unfavorable: only 47% (stage IIB) to 18% (stage IVB). Except for allogeneic stem cell transplantation, there is currently no cure for CTCL and thus treatment approaches are palliative, focusing on patients' health-related quality of life. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12688/f1000research.21922.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202086PMC

Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma.

J Immunother Cancer 2020 May;8(1)

Department of Pediatric Hematology and Oncology, Greifswald University Medicine, Greifswald, Germany.

Background: Neuroblastoma (NB) is the most frequent extracranial solid tumor in children. More than 50% of patients present with widespread (stage M) or refractory disease. In these patients, event-free and overall survival was improved by the addition of the anti-disialoganglioside antibody dinutuximab beta (DB) following multimodal conventional therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jitc-2020-000540DOI Listing

Negative illness perceptions are related to more fatigue among haematological cancer survivors: a PROFILES study.

Acta Oncol 2020 May 15:1-8. Epub 2020 May 15.

Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.

: The common sense model provides a theoretical framework for understanding substantial fatigue among (haematological) cancer survivors based on their illness perceptions. We therefore examined the associations between modifiable illness perceptions and substantial fatigue while controlling for sociodemographic, clinical, and psychological factors (symptoms of depression and anxiety) among haematological cancer survivors.: Data from the population-based PROFILES registry were used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2020.1759823DOI Listing

MCT8 Deficiency: The Road to Therapies for a Rare Disease.

Front Neurosci 2020 28;14:380. Epub 2020 Apr 28.

Department of Endocrine and Nervous System Pathophysiology, Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid (UAM), Madrid, Spain.

Allan-Herndon-Dudley syndrome is a rare disease caused by inactivating mutations in the gene, which encodes the monocarboxylate transporter 8 (MCT8), a transmembrane transporter specific for thyroid hormones (T3 and T4). Lack of MCT8 function produces serious neurological disturbances, most likely due to impaired transport of thyroid hormones across brain barriers during development resulting in severe brain hypothyroidism. Patients also suffer from thyrotoxicity in other organs due to the presence of a high concentration of T3 in the serum. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fnins.2020.00380DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198743PMC

Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas.

Br J Dermatol 2020 May 14. Epub 2020 May 14.

Department of Dermatology, Saint-Louis Hospital, AP-HP, Paris, France.

Ifosfamide + etoposide (I+E) have been used to treat lymphomas, combined with platinum-based agents in Hodgkin disease or non-Hodgkin lymphomas including peripheral T-cell lymphomas. Monoclonal antibodies have induced long-term remissions in CTCL but are usually poorly effective in transformed disease. Allogeneic hematopoietic stem cell transplantation (alloHSCT) holds a potential for cure but relies on the existence of a pre-transplant CR which may require the use of chemotherapeutic regimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.19220DOI Listing

The COVID-19 pandemic: A rapid global response for children with cancer from SIOP, COG, SIOP-E, SIOP-PODC, IPSO, PROS, CCI, and St Jude Global.

Pediatr Blood Cancer 2020 07 13;67(7):e28409. Epub 2020 May 13.

International Society of Paediatric Oncology (SIOP), UCL Great Ormond Street Institute of Child Health, University College London, London, UK.

The COVID-19 pandemic is one of the most serious global challenges to delivering affordable and equitable treatment to children with cancer we have witnessed in the last few decades. This Special Report aims to summarize general principles for continuing multidisciplinary care during the SARS-CoV-2 (COVID-19) pandemic. With contributions from the leadership of the International Society for Pediatric Oncology (SIOP), Children's Oncology Group (COG), St Jude Global program, and Childhood Cancer International, we have sought to provide a framework for healthcare teams caring for children with cancer during the pandemic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.28409DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235469PMC

[Comparisons of clinical characteristics and prognosis between patients with primary and secondary thyroid lymphoma].

Zhonghua Xue Ye Xue Za Zhi 2019 Jul;40(7):568-572

Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, State Key Laboratory of Medical Genomics, Shanghai 200025, China.

To compare clinical characteristics and prognosis between patients with primary (PTL) and secondary thyroid lymphoma (STL) . A retrospective analysis was performed on 46 patients with thyroid lymphoma (PTL 19, STL 27) from January 2002 to October 2018. ①PTL group included 4 males and 15 females, with a median age of 57 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.07.006DOI Listing

Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease.

Blood Adv 2020 May;4(9):2064-2072

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.

Controversy exists regarding the definition and prognostic significance of bulk in advanced-stage (stage III/IV) Hodgkin lymphoma (ASHL), and bulk location (mediastinum vs other sites) further complicated the setting. This retrospective, multi-institutional study comprised 814 ASHL patients between 2000 and 2010 and aimed to evaluate the significance of bulk in ASHL. End points of interest included progression-free survival (PFS) and overall survival (OS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2019001265DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218436PMC

Hepatitis C Virus Infection and Treatment as Independent Prognostic Factors in Diffuse Large B-Cell Lymphoma Egyptian Patients.

Curr Cancer Drug Targets 2020 May 10. Epub 2020 May 10.

Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Suez Canal University. Egypt.

Background: Egypt is one of highest hepatitis C virus (HCV) endemic areas. Chronic HCV infection has extra-hepatic manifestations, including non-Hodgkin lymphoma (NHL). Diffuse large B-cell lymphoma (DLBCL) is commonly associated with HCV infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009620666200511084731DOI Listing
May 2020
3.522 Impact Factor

Outcome at the end of treatment of patients with common and curable childhood cancer types in Blantyre, Malawi.

Pediatr Blood Cancer 2020 Jul 11;67(7):e28322. Epub 2020 May 11.

Academy Outreach and Department of Solid Tumours, Princess Máxima Center for Paediatric Oncology, Utrecht, The Netherlands.

Background: The WHO Global Initiative for Childhood Cancer aims to increase survival to at least 60% for all children with cancer globally, with initial focus on six common curable cancer types. Frequent causes of treatment failure in low income countries (LICs) are treatment abandonment and death during treatment. Here, we report on the outcome at the end of treatment of patients with newly diagnosed common and curable cancer types, admitted in the Queen Elizabeth Central Hospital, Blantyre, Malawi. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.28322DOI Listing
July 2020
2.562 Impact Factor

Hodgkin Lymphoma: 2020 update on diagnosis, risk-stratification, and management.

Authors:
Stephen M Ansell

Am J Hematol 2020 May 8. Epub 2020 May 8.

Mayo Clinic, United States.

Disease Overview: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8,480 new patients annually and representing approximately 10% of all lymphomas in the United States.

Diagnosis: HL is composed of two distinct disease entities: classical HL and nodular lymphocyte predominant HL. Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte-rich HL are subgroups of classical HL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25856DOI Listing

Long-term Hodgkin Lymphoma Survivors: A Glimpse of What Happens 10 Years After Treatment.

Clin Lymphoma Myeloma Leuk 2020 Mar 20. Epub 2020 Mar 20.

Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari, Bari, Italy. Electronic address:

Introduction: This retrospective study was focused on 96 patients (median age at diagnosis, 35 years) with newly diagnosed Hodgkin lymphoma (HL) treated at the University Hospital of Bari (Italy) between 2005 and 2008, to evaluate the outcome and the long-term toxicity.

Patients And Methods: First-line chemotherapy was ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) in all patients; 49 (51%) patients had undergone radiotherapy. At the end of treatment, 75 (78%) patients were in complete remission (CR); 18 (24%) of 75 patients relapsed after first-line treatment; 20 (21%) underwent autologous hematopoietic stem cell transplantation, and 3 (3%) underwent allogeneic stem cell transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.03.006DOI Listing

Burkitt's lymphoma of the prostate presenting as acute urinary retention: a case report.

BMC Urol 2020 May 6;20(1):53. Epub 2020 May 6.

Department of Urology and Pediatric Urology, University Hospital, Philipps-University Marburg, Baldingerstr. 1, 35043, Marburg, Germany.

Background: Non-Hodgkin lymphomas, which include Burkitt's lymphoma, affect the prostate in only 0.1% of cases. They most commonly present as painless lymphadenopathy elsewhere in the body and can cause abdominal or thoracic pain and systemic symptoms such as fever, weight loss and night sweats. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12894-020-00616-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203870PMC

Association between C-myc and K-ras gene polymorphisms and non-Hodgkin lymphoma.

Eur Rev Med Pharmacol Sci 2020 Apr;24(8):4396-4403

Department of Hematology, the First Affiliated Hospital of Anhui Medical University, Hefei, China.

Objective: To explore the association between c-myc and K-ras gene polymorphisms and non-Hodgkin lymphoma (NHL).

Patients And Methods: A total of 200 NHL patients in our hospital in the past 3 years were collected as disease group, while 200 healthy people were taken as control group. The genomic deoxyribonucleic acid (DNA) in the peripheral blood was extracted in both groups, amplified via Polymerase Chain Reaction (PCR) and sent to the company for the detection of c-myc and K-ras gene polymorphisms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26355/eurrev_202004_21021DOI Listing

Clinico-pathological significance of immunohistochemically marked tumor-associated macrophage in classic Hodgkin lymphoma.

J Egypt Natl Canc Inst 2020 Apr 15;32(1):18. Epub 2020 Apr 15.

Clinical Hematology Internal Medicine Department, Oncology Center, Faculty of Medicine, Mansoura University, Mansoura, 35516, Egypt.

Background: Tumor-associated macrophages (TAM) are pivotal in remodeling of the tumor immune microenvironment and clinical outcome. Herein, we aim to evaluate the impact of immunohistochemical (IHC) expression of CD68 and CD163 in TAM on clinico-pathological features, patients' response to therapy and the overall survival (OS).

Results: This retrospective study was performed on paraffin-embedded tissue blocks of 100 classic Hodgkin Lymphoma (cHL) cases diagnosed and treated at our Institution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s43046-020-00029-1DOI Listing

Management of Older Adults with Mantle Cell Lymphoma.

Drugs Aging 2020 May 5. Epub 2020 May 5.

Department of Hematology and Medical Oncology, Winship Cancer Institute At Emory University, 1365C Clifton Road, NE, Suite B4000D, Atlanta, GA, 30322, USA.

Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma that is largely a disease of older adults with a median age at diagnosis of 67 years. MCL is considered incurable with current therapies and has historically been associated with a poor prognosis. A subset of patients will present with features of more indolent disease and can be safely observed for a period of time after diagnosis, but the majority will require treatment at some point in the disease course. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40266-020-00765-yDOI Listing

T-cell lymphomas in a tertiary care center of Mangalore.

J Cancer Res Ther 2020 Jan-Mar;16(1):94-97

Departments of Pathology and Oncology, Kasturba Medical College, M.A.H.E., Mangalore, Karnataka, India.

Background: The clinicomorphology and immunohistochemical features of T-cell lymphomas have been documented.

Aim: The aim of the study was to evaluate the spectrum of clincopathological features of T-cell lymphoma with immunohistochemistry correlation in a tertiary care center.

Materials And Methods: The present study was conducted on 19 biopsy specimens received from the Department of Pathology, Kasturba Medical College, from referral hospitals of Mangalore city. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jcrt.JCRT_60_17DOI Listing

Multidetector computed tomography evaluation of synchronous lymphoma and other solid malignancies.

J Cancer Res Ther 2020 Jan-Mar;16(1):60-65

Department of Occupational Health and Industrial Medicine, Public Health and Community Medicine, Mansoura Faculty of Medicine, Mansoura University, Mansoura University, Mansoura, Egypt.

Objective: The objective of this study is to review the multidetector computed tomography (MDCT) findings of synchronous lymphoma and other solid malignancies.

Patients And Methods: This retrospective study included 18 patients confirmed with diagnosis of lymphoma and other solid malignancies. They were 8 women and 10 men (mean age, 62. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jcrt.JCRT_325_17DOI Listing

Xist noncoding RNA could act as a tumor suppressor gene in patients with classical Hodgkin's disease.

Authors:
Stefano Parodi

J Cancer Res Ther 2020 Jan-Mar;16(1):7-12

Institute of Electronics, Computer and Telecommunication Engineering, National Research Council of Italy, Genoa, Italy.

Background: Xist is a long noncoding RNA involved in the X chromosome inactivation in females. It may act as an onco-suppressor gene in hematologic malignancies, and its activity is strongly dependent from SATB1 gene expression. However, its potential role in Hodgkin's disease (HD) onset and progression is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jcrt.JCRT_1055_16DOI Listing

Combined modality treatment: Outcome in patients with Hodgkin's lymphoma.

J Cancer Res Ther 2020 Jan-Mar;16(1):1-6

Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Background: Hodgkin's lymphoma (HL) can be treated with combined modality treatment (CMT) to limit long-term toxicities in the early favorable stage. Early unfavorable and advanced stage HL is mainly treated with chemotherapy followed by radiation to the bulky site. This study examines the impact of CMT in early as well as advanced stage HL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jcrt.JCRT_465_17DOI Listing

New biomarkers in non-Hodgkin lymphoma and acute leukemias.

Adv Clin Chem 2020 3;96:19-53. Epub 2020 Mar 3.

Unidad de Investigación Biomédica 02, UMAE HE, CMNO, IMSS, Guadalajara, Jalisco, Mexico; Programa Internacional, Facultad de Medicina, Universidad Autónoma de Guadalajara, Zapopan, Jalisco, Mexico; Departamento de Inmunologia y Reumatologia, Hospital General de Occidente, Secretaria de Salud Jalisco, Zapopan, Jalisco, Mexico. Electronic address:

Biomarkers play a critical role in the medical care of patients with cancer, including in early detection of the disease, diagnostic accuracy, risk stratification, treatment, and follow-up. Biomarkers in hematological malignancies can support the redefinition of the diagnosis and adjustments in the treatment plan. Biomarkers can be classified into 4 categories: (1) protein antigens, (2) cytogenetic abnormalities, (3) genetic polymorphisms, and (4) gene expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acc.2019.11.002DOI Listing